Woodley Farra Manion Portfolio Management Inc. lowered its position in shares of Novartis AG (NYSE:NVS – Free Report) by 17.7% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 21,644 shares of the company’s stock after selling 4,664 shares during the quarter. Woodley Farra Manion Portfolio Management Inc.’s holdings in Novartis were worth $3,086,000 as of its most recent filing with the SEC.
Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. Lido Advisors LLC grew its holdings in Novartis by 7.3% in the third quarter. Lido Advisors LLC now owns 39,501 shares of the company’s stock valued at $5,632,000 after purchasing an additional 2,697 shares during the period. Csenge Advisory Group raised its holdings in shares of Novartis by 6.7% in the 3rd quarter. Csenge Advisory Group now owns 17,186 shares of the company’s stock worth $2,450,000 after purchasing an additional 1,076 shares during the period. Gen Wealth Partners Inc purchased a new position in shares of Novartis in the 3rd quarter worth about $30,000. Kestra Investment Management LLC raised its holdings in shares of Novartis by 6.4% in the 3rd quarter. Kestra Investment Management LLC now owns 2,167 shares of the company’s stock worth $309,000 after purchasing an additional 130 shares during the period. Finally, Allspring Global Investments Holdings LLC lifted its stake in shares of Novartis by 2.1% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 82,309 shares of the company’s stock valued at $11,610,000 after purchasing an additional 1,696 shares in the last quarter. Hedge funds and other institutional investors own 13.12% of the company’s stock.
Wall Street Analysts Forecast Growth
A number of analysts have recently issued reports on the company. Sanford C. Bernstein reiterated a “neutral” rating on shares of Novartis in a report on Wednesday, July 22nd. Berenberg Bank cut their price target on shares of Novartis from $147.00 to $130.00 and set a “hold” rating on the stock in a report on Friday, September 11th. Morgan Stanley reaffirmed an “overweight” rating and set a $163.00 price target on shares of Novartis in a research report on Wednesday, October 28th. Wall Street Zen raised shares of Novartis from a “hold” rating to a “buy” rating in a research report on Saturday, October 31st. Finally, DZ Bank started coverage on shares of Novartis in a research note on Wednesday, October 28th. They set a “hold” rating for the company. Six equities research analysts have rated the stock with a Buy rating, nine have given a Hold rating and three have assigned a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $152.25.
Novartis Stock Down 0.2%
Shares of NYSE NVS opened at $163.28 on Wednesday. The stock has a fifty day moving average price of $149.24 and a 200 day moving average price of $152.44. The company has a current ratio of 0.88, a quick ratio of 0.70 and a debt-to-equity ratio of 0.98. Novartis AG has a 12-month low of $123.24 and a 12-month high of $170.46. The company has a market cap of $311.57 billion, a P/E ratio of 31.16, a P/E/G ratio of 3.01 and a beta of 0.40.
Novartis (NYSE:NVS – Get Free Report) last issued its quarterly earnings data on Tuesday, October 27th. The company reported $2.46 EPS for the quarter, topping analysts’ consensus estimates of $2.25 by $0.21. The company had revenue of $15.03 billion for the quarter, compared to analysts’ expectations of $14.53 billion. Novartis had a return on equity of 41.04% and a net margin of 18.11%. The firm’s quarterly revenue was up 4.4% on a year-over-year basis. During the same quarter in the previous year, the firm posted $2.25 earnings per share. Research analysts anticipate that Novartis AG will post 9.04 EPS for the current fiscal year.
Novartis Company Profile
Novartis AG is a Swiss pharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative medicines. Its research and products address conditions in areas including oncology, immunology, neuroscience, and cardiovascular, renal and metabolic health. The company’s medicines include treatments such as Kisqali for certain breast cancers, Cosentyx for inflammatory diseases, Entresto for heart failure and Kesimpta for multiple sclerosis. Its portfolio also includes radioligand therapies and other specialized treatments.
Featured Articles
- Five stocks we like better than Novartis
- Why Kinder Morgan’s Chairman Just Bought $15 Million in Stock
- Rocket Lab’s Record Backlog Could Fuel a Rebound, But Neutron Raises the Stakes
- Don’t Let Their Low Yields Fool You: 3 Dividend Stocks Worth Watching
- A $4 Billion Jolt: NRG Energy Powers Data Center Ambitions
Want to see what other hedge funds are holding NVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novartis AG (NYSE:NVS – Free Report).
Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.
